Tackling polycystic ovary syndrome.
Up to one-third of women in the UK have polycystic ovaries (i.e. 10 or more follicles per ovary detected on ultrasound). An estimated one-third of these women have polycystic ovary syndrome, usually defined in the UK as polycystic ovaries together with one or more characteristic features (hirsutism, male-pattern baldness, acne, oligomenorrhoea or amenorrhoea, obesity, or raised serum concentrations of testosterone and/or luteinising hormone [LH]). The metabolic abnormalities often associated with polycystic ovary syndrome (insulin resistance and abnormal serum lipid concentrations) also put some women with the syndrome at increased risk of developing diabetes mellitus. Here, we review the management of women with polycystic ovary syndrome.
D000726:Androgen Antagonists / Q000627:therapeutic use; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008019:Life Style; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000175:diagnosis / Q000628:therapy*
D000726:Androgen Antagonists; D005300:Fertility Agents, Female; D007004:Hypoglycemic Agents; D000451:Mineralocorticoid Receptor Antagonists